Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to 0.53%.

  • C4 Therapeutics' Return on Capital Employed fell 1700.0% to 0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53%, marking a year-over-year decrease of 1700.0%. This contributed to the annual value of 0.38% for FY2024, which is 100.0% up from last year.
  • Latest data reveals that C4 Therapeutics reported Return on Capital Employed of 0.53% as of Q3 2025, which was down 1700.0% from 0.47% recorded in Q2 2025.
  • C4 Therapeutics' Return on Capital Employed's 5-year high stood at 0.18% during Q4 2021, with a 5-year trough of 0.53% in Q3 2025.
  • Its 5-year average for Return on Capital Employed is 0.33%, with a median of 0.36% in 2024.
  • Per our database at Business Quant, C4 Therapeutics' Return on Capital Employed tumbled by -2100bps in 2023 and then soared by 800bps in 2024.
  • Over the past 5 years, C4 Therapeutics' Return on Capital Employed (Quarter) stood at 0.18% in 2021, then crashed by -79bps to 0.32% in 2022, then tumbled by -38bps to 0.45% in 2023, then increased by 16bps to 0.38% in 2024, then plummeted by -41bps to 0.53% in 2025.
  • Its Return on Capital Employed stands at 0.53% for Q3 2025, versus 0.47% for Q2 2025 and 0.4% for Q1 2025.